Skip to main content
NCBI home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1999 Jan;8(1):180–195. doi: 10.1110/ps.8.1.180

Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease.

J Trylska 1, J Antosiewicz 1, M Geller 1, C N Hodge 1, R M Klabe 1, M S Head 1, M K Gilson 1
PMCID: PMC2144115  PMID: 10210196

Abstract

The aspartyl dyad of free HIV-1 protease has apparent pK(a)s of approximately 3 and approximately 6, but recent NMR studies indicate that the aspartyl dyad is fixed in the doubly protonated form over a wide pH range when cyclic urea inhibitors are bound, and in the monoprotonated form when the inhibitor KNI-272 is bound. We present computations and measurements related to these changes in protonation and to the thermodynamic linkage between protonation and inhibition. The Poisson-Boltzmann model of electrostatics is used to compute the apparent pK(a)s of the aspartyl dyad in the free enzyme and in complexes with four different inhibitors. The calculations are done with two parameter sets. One assigns epsilon = 4 to the solute interior and uses a detailed model of ionization; the other uses epsilon = 20 for the solute interior and a simplified representation of ionization. For the free enzyme, both parameter sets agree well with previously measured apparent pK(a)s of approximately 3 and approximately 6. However, the calculations with an internal dielectric constant of 4 reproduce the large pKa shifts upon binding of inhibitors, but the calculations with an internal dielectric constant of 20 do not. This observation has implications for the accurate calculation of pK(a)s in complex protein environments. Because binding of a cyclic urea inhibitor shifts the pK(a)s of the aspartyl dyad, changing the pH is expected to change its apparent binding affinity. However, we find experimentally that the affinity is independent of pH from 5.5 to 7.0. Possible explanations for this discrepancy are discussed.

Full Text

The Full Text of this article is available as a PDF (359.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexov E. G., Gunner M. R. Incorporating protein conformational flexibility into the calculation of pH-dependent protein properties. Biophys J. 1997 May;72(5):2075–2093. doi: 10.1016/S0006-3495(97)78851-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Antosiewicz J., McCammon J. A., Gilson M. K. Prediction of pH-dependent properties of proteins. J Mol Biol. 1994 May 6;238(3):415–436. doi: 10.1006/jmbi.1994.1301. [DOI] [PubMed] [Google Scholar]
  3. Antosiewicz J., McCammon J. A., Gilson M. K. The determinants of pKas in proteins. Biochemistry. 1996 Jun 18;35(24):7819–7833. doi: 10.1021/bi9601565. [DOI] [PubMed] [Google Scholar]
  4. Baldwin E. T., Bhat T. N., Gulnik S., Liu B., Topol I. A., Kiso Y., Mimoto T., Mitsuya H., Erickson J. W. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure. 1995 Jun 15;3(6):581–590. doi: 10.1016/s0969-2126(01)00192-7. [DOI] [PubMed] [Google Scholar]
  5. Bashford D., Case D. A., Dalvit C., Tennant L., Wright P. E. Electrostatic calculations of side-chain pK(a) values in myoglobin and comparison with NMR data for histidines. Biochemistry. 1993 Aug 10;32(31):8045–8056. doi: 10.1021/bi00082a027. [DOI] [PubMed] [Google Scholar]
  6. Bashford D., Gerwert K. Electrostatic calculations of the pKa values of ionizable groups in bacteriorhodopsin. J Mol Biol. 1992 Mar 20;224(2):473–486. doi: 10.1016/0022-2836(92)91009-e. [DOI] [PubMed] [Google Scholar]
  7. Bashford D., Karplus M. pKa's of ionizable groups in proteins: atomic detail from a continuum electrostatic model. Biochemistry. 1990 Nov 6;29(44):10219–10225. doi: 10.1021/bi00496a010. [DOI] [PubMed] [Google Scholar]
  8. Bernstein F. C., Koetzle T. F., Williams G. J., Meyer E. F., Jr, Brice M. D., Rodgers J. R., Kennard O., Shimanouchi T., Tasumi M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol. 1977 May 25;112(3):535–542. doi: 10.1016/s0022-2836(77)80200-3. [DOI] [PubMed] [Google Scholar]
  9. Beroza P., Fredkin D. R., Okamura M. Y., Feher G. Protonation of interacting residues in a protein by a Monte Carlo method: application to lysozyme and the photosynthetic reaction center of Rhodobacter sphaeroides. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5804–5808. doi: 10.1073/pnas.88.13.5804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Beveridge A. J., Heywood G. C. A quantum mechanical study of the active site of aspartic proteinases. Biochemistry. 1993 Apr 6;32(13):3325–3333. doi: 10.1021/bi00064a015. [DOI] [PubMed] [Google Scholar]
  11. Brocklehurst K. A sound basis for pH-dependent kinetic studies on enzymes. Protein Eng. 1994 Mar;7(3):291–299. doi: 10.1093/protein/7.3.291. [DOI] [PubMed] [Google Scholar]
  12. Brünger A. T., Karplus M. Polar hydrogen positions in proteins: empirical energy placement and neutron diffraction comparison. Proteins. 1988;4(2):148–156. doi: 10.1002/prot.340040208. [DOI] [PubMed] [Google Scholar]
  13. Cheng Y. S., Yin F. H., Foundling S., Blomstrom D., Kettner C. A. Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9660–9664. doi: 10.1073/pnas.87.24.9660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cleland W. W. Determining the chemical mechanisms of enzyme-catalyzed reactions by kinetic studies. Adv Enzymol Relat Areas Mol Biol. 1977;45:273–387. doi: 10.1002/9780470122907.ch4. [DOI] [PubMed] [Google Scholar]
  15. Debouck C., Gorniak J. G., Strickler J. E., Meek T. D., Metcalf B. W., Rosenberg M. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A. 1987 Dec;84(24):8903–8906. doi: 10.1073/pnas.84.24.8903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Erickson-Viitanen S., Klabe R. M., Cawood P. G., O'Neal P. L., Meek J. L. Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323. Antimicrob Agents Chemother. 1994 Jul;38(7):1628–1634. doi: 10.1128/aac.38.7.1628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Geller M., Miller M., Swanson S. M., Maizel J. Analysis of the structure of HIV-1 protease complexed with a hexapeptide inhibitor. Part II: Molecular dynamic studies of the active site region. Proteins. 1997 Feb;27(2):195–203. [PubMed] [Google Scholar]
  18. Gibas C. J., Subramaniam S. Explicit solvent models in protein pKa calculations. Biophys J. 1996 Jul;71(1):138–147. doi: 10.1016/S0006-3495(96)79209-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gilson M. K., Honig B. H. Energetics of charge-charge interactions in proteins. Proteins. 1988;3(1):32–52. doi: 10.1002/prot.340030104. [DOI] [PubMed] [Google Scholar]
  20. Gilson M. K., Honig B. H. The dielectric constant of a folded protein. Biopolymers. 1986 Nov;25(11):2097–2119. doi: 10.1002/bip.360251106. [DOI] [PubMed] [Google Scholar]
  21. Gilson M. K., Honig B. Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies, and conformational analysis. Proteins. 1988;4(1):7–18. doi: 10.1002/prot.340040104. [DOI] [PubMed] [Google Scholar]
  22. Gilson M. K. Multiple-site titration and molecular modeling: two rapid methods for computing energies and forces for ionizable groups in proteins. Proteins. 1993 Mar;15(3):266–282. doi: 10.1002/prot.340150305. [DOI] [PubMed] [Google Scholar]
  23. Gilson M. K., Rashin A., Fine R., Honig B. On the calculation of electrostatic interactions in proteins. J Mol Biol. 1985 Aug 5;184(3):503–516. doi: 10.1016/0022-2836(85)90297-9. [DOI] [PubMed] [Google Scholar]
  24. Grant S. K., Deckman I. C., Culp J. S., Minnich M. D., Brooks I. S., Hensley P., Debouck C., Meek T. D. Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases. Biochemistry. 1992 Oct 6;31(39):9491–9501. doi: 10.1021/bi00154a023. [DOI] [PubMed] [Google Scholar]
  25. Graves M. C., Lim J. J., Heimer E. P., Kramer R. A. An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2449–2453. doi: 10.1073/pnas.85.8.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hansen J., Billich S., Schulze T., Sukrow S., Moelling K. Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. EMBO J. 1988 Jun;7(6):1785–1791. doi: 10.1002/j.1460-2075.1988.tb03009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hyland L. J., Tomaszek T. A., Jr, Meek T. D. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry. 1991 Aug 27;30(34):8454–8463. doi: 10.1021/bi00098a024. [DOI] [PubMed] [Google Scholar]
  28. Ido E., Han H. P., Kezdy F. J., Tang J. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J Biol Chem. 1991 Dec 25;266(36):24359–24366. [PubMed] [Google Scholar]
  29. Jadhav P. K., Ala P., Woerner F. J., Chang C. H., Garber S. S., Anton E. D., Bacheler L. T. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J Med Chem. 1997 Jan 17;40(2):181–191. doi: 10.1021/jm960586t. [DOI] [PubMed] [Google Scholar]
  30. Jaskólski M., Tomasselli A. G., Sawyer T. K., Staples D. G., Heinrikson R. L., Schneider J., Kent S. B., Wlodawer A. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry. 1991 Feb 12;30(6):1600–1609. doi: 10.1021/bi00220a023. [DOI] [PubMed] [Google Scholar]
  31. Kageyama S., Mimoto T., Murakawa Y., Nomizu M., Ford H., Jr, Shirasaka T., Gulnik S., Erickson J., Takada K., Hayashi H. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother. 1993 Apr;37(4):810–817. doi: 10.1128/aac.37.4.810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kick E. K., Roe D. C., Skillman A. G., Liu G., Ewing T. J., Sun Y., Kuntz I. D., Ellman J. A. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chem Biol. 1997 Apr;4(4):297–307. doi: 10.1016/s1074-5521(97)90073-9. [DOI] [PubMed] [Google Scholar]
  33. Klapper I., Hagstrom R., Fine R., Sharp K., Honig B. Focusing of electric fields in the active site of Cu-Zn superoxide dismutase: effects of ionic strength and amino-acid modification. Proteins. 1986 Sep;1(1):47–59. doi: 10.1002/prot.340010109. [DOI] [PubMed] [Google Scholar]
  34. Knowles J. R. The intrinsic pKa-values of functional groups in enzymes: improper deductions from the pH-dependence of steady-state parameters. CRC Crit Rev Biochem. 1976 Nov;4(2):165–173. doi: 10.3109/10409237609105457. [DOI] [PubMed] [Google Scholar]
  35. Kohl N. E., Emini E. A., Schleif W. A., Davis L. J., Heimbach J. C., Dixon R. A., Scolnick E. M., Sigal I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686–4690. doi: 10.1073/pnas.85.13.4686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Lam P. Y., Jadhav P. K., Eyermann C. J., Hodge C. N., Ru Y., Bacheler L. T., Meek J. L., Otto M. J., Rayner M. M., Wong Y. N. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science. 1994 Jan 21;263(5145):380–384. doi: 10.1126/science.8278812. [DOI] [PubMed] [Google Scholar]
  37. Lam P. Y., Ru Y., Jadhav P. K., Aldrich P. E., DeLucca G. V., Eyermann C. J., Chang C. H., Emmett G., Holler E. R., Daneker W. F. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem. 1996 Aug 30;39(18):3514–3525. doi: 10.1021/jm9602571. [DOI] [PubMed] [Google Scholar]
  38. Liu H., Müller-Plathe F., van Gunsteren W. F. A combined quantum/classical molecular dynamics study of the catalytic mechanism of HIV protease. J Mol Biol. 1996 Aug 23;261(3):454–469. doi: 10.1006/jmbi.1996.0476. [DOI] [PubMed] [Google Scholar]
  39. Matthew J. B., Gurd F. R., Garcia-Moreno B., Flanagan M. A., March K. L., Shire S. J. pH-dependent processes in proteins. CRC Crit Rev Biochem. 1985;18(2):91–197. doi: 10.3109/10409238509085133. [DOI] [PubMed] [Google Scholar]
  40. McIntosh L. P., Hand G., Johnson P. E., Joshi M. D., Körner M., Plesniak L. A., Ziser L., Wakarchuk W. W., Withers S. G. The pKa of the general acid/base carboxyl group of a glycosidase cycles during catalysis: a 13C-NMR study of bacillus circulans xylanase. Biochemistry. 1996 Aug 6;35(31):9958–9966. doi: 10.1021/bi9613234. [DOI] [PubMed] [Google Scholar]
  41. Mildner A. M., Rothrock D. J., Leone J. W., Bannow C. A., Lull J. M., Reardon I. M., Sarcich J. L., Howe W. J., Tomich C. S., Smith C. W. The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry. 1994 Aug 16;33(32):9405–9413. doi: 10.1021/bi00198a005. [DOI] [PubMed] [Google Scholar]
  42. Miller M., Geller M., Gribskov M., Kent S. B. Analysis of the structure of chemically synthesized HIV-1 protease complexed with a hexapeptide inhibitor. Part I: Crystallographic refinement of 2 A data. Proteins. 1997 Feb;27(2):184–194. doi: 10.1002/(sici)1097-0134(199702)27:2<184::aid-prot4>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  43. Miller M., Schneider J., Sathyanarayana B. K., Toth M. V., Marshall G. R., Clawson L., Selk L., Kent S. B., Wlodawer A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science. 1989 Dec 1;246(4934):1149–1152. doi: 10.1126/science.2686029. [DOI] [PubMed] [Google Scholar]
  44. Moore M. L., Bryan W. M., Fakhoury S. A., Magaard V. W., Huffman W. F., Dayton B. D., Meek T. D., Hyland L., Dreyer G. B., Metcalf B. W. Peptide substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun. 1989 Mar 15;159(2):420–425. doi: 10.1016/0006-291x(89)90008-9. [DOI] [PubMed] [Google Scholar]
  45. Muir T. W., Williams M. J., Kent S. B. Detection of synthetic protein isomers and conformers by electrospray mass spectrometry. Anal Biochem. 1995 Jan 1;224(1):100–109. doi: 10.1006/abio.1995.1013. [DOI] [PubMed] [Google Scholar]
  46. Oberoi H., Allewell N. M. Multigrid solution of the nonlinear Poisson-Boltzmann equation and calculation of titration curves. Biophys J. 1993 Jul;65(1):48–55. doi: 10.1016/S0006-3495(93)81032-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Oda Y., Yamazaki T., Nagayama K., Kanaya S., Kuroda Y., Nakamura H. Individual ionization constants of all the carboxyl groups in ribonuclease HI from Escherichia coli determined by NMR. Biochemistry. 1994 May 3;33(17):5275–5284. doi: 10.1021/bi00183a034. [DOI] [PubMed] [Google Scholar]
  48. Rich D. H., Green J., Toth M. V., Marshall G. R., Kent S. B. Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. J Med Chem. 1990 May;33(5):1285–1288. doi: 10.1021/jm00167a003. [DOI] [PubMed] [Google Scholar]
  49. Schock H. B., Garsky V. M., Kuo L. C. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem. 1996 Dec 13;271(50):31957–31963. doi: 10.1074/jbc.271.50.31957. [DOI] [PubMed] [Google Scholar]
  50. Shire S. J., Hanania G. I., Gurd F. R. Electrostatic effects in myoglobin. Hydrogen ion equilibria in sperm whale ferrimyoglobin. Biochemistry. 1974 Jul 2;13(14):2967–2974. doi: 10.1021/bi00711a028. [DOI] [PubMed] [Google Scholar]
  51. Silva A. M., Cachau R. E., Sham H. L., Erickson J. W. Inhibition and catalytic mechanism of HIV-1 aspartic protease. J Mol Biol. 1996 Jan 19;255(2):321–346. doi: 10.1006/jmbi.1996.0026. [DOI] [PubMed] [Google Scholar]
  52. Simonson T., Perahia D., Brünger A. T. Microscopic theory of the dielectric properties of proteins. Biophys J. 1991 Mar;59(3):670–690. doi: 10.1016/S0006-3495(91)82282-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Simonson T., Perahia D. Internal and interfacial dielectric properties of cytochrome c from molecular dynamics in aqueous solution. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1082–1086. doi: 10.1073/pnas.92.4.1082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Smith R., Brereton I. M., Chai R. Y., Kent S. B. Ionization states of the catalytic residues in HIV-1 protease. Nat Struct Biol. 1996 Nov;3(11):946–950. doi: 10.1038/nsb1196-946. [DOI] [PubMed] [Google Scholar]
  55. Spinelli S., Liu Q. Z., Alzari P. M., Hirel P. H., Poljak R. J. The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie. 1991 Nov;73(11):1391–1396. doi: 10.1016/0300-9084(91)90169-2. [DOI] [PubMed] [Google Scholar]
  56. Stivers J. T., Abeygunawardana C., Mildvan A. S., Hajipour G., Whitman C. P. 4-Oxalocrotonate tautomerase: pH dependence of catalysis and pKa values of active site residues. Biochemistry. 1996 Jan 23;35(3):814–823. doi: 10.1021/bi9510789. [DOI] [PubMed] [Google Scholar]
  57. Tipton K. F., Dixon H. B. Effects of pH on enzymes. Methods Enzymol. 1979;63:183–234. doi: 10.1016/0076-6879(79)63011-2. [DOI] [PubMed] [Google Scholar]
  58. Todd M. J., Semo N., Freire E. The structural stability of the HIV-1 protease. J Mol Biol. 1998 Oct 23;283(2):475–488. doi: 10.1006/jmbi.1998.2090. [DOI] [PubMed] [Google Scholar]
  59. Tomasselli A. G., Mildner A. M., Rothrock D. J., Sarcich J. L., Lull J., Leone J., Heinrikson R. L. Mutants of HIV-1 protease with enhanced stability to autodegradation. Adv Exp Med Biol. 1995;362:387–398. doi: 10.1007/978-1-4615-1871-6_51. [DOI] [PubMed] [Google Scholar]
  60. WYMAN J. THE BINDING POTENTIAL, A NEGLECTED LINKAGE CONCEPT. J Mol Biol. 1965 Mar;11:631–644. doi: 10.1016/s0022-2836(65)80017-1. [DOI] [PubMed] [Google Scholar]
  61. Wang Y. X., Freedberg D. I., Yamazaki T., Wingfield P. T., Stahl S. J., Kaufman J. D., Kiso Y., Torchia D. A. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry. 1996 Aug 6;35(31):9945–9950. doi: 10.1021/bi961268z. [DOI] [PubMed] [Google Scholar]
  62. Warwicker J., Watson H. C. Calculation of the electric potential in the active site cleft due to alpha-helix dipoles. J Mol Biol. 1982 Jun 5;157(4):671–679. doi: 10.1016/0022-2836(82)90505-8. [DOI] [PubMed] [Google Scholar]
  63. Wlodawer A., Miller M., Jaskólski M., Sathyanarayana B. K., Baldwin E., Weber I. T., Selk L. M., Clawson L., Schneider J., Kent S. B. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989 Aug 11;245(4918):616–621. doi: 10.1126/science.2548279. [DOI] [PubMed] [Google Scholar]
  64. Xie D., Gulnik S., Collins L., Gustchina E., Suvorov L., Erickson J. W. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues. Biochemistry. 1997 Dec 23;36(51):16166–16172. doi: 10.1021/bi971550l. [DOI] [PubMed] [Google Scholar]
  65. Yang A. S., Gunner M. R., Sampogna R., Sharp K., Honig B. On the calculation of pKas in proteins. Proteins. 1993 Mar;15(3):252–265. doi: 10.1002/prot.340150304. [DOI] [PubMed] [Google Scholar]
  66. Yang A. S., Honig B. On the pH dependence of protein stability. J Mol Biol. 1993 May 20;231(2):459–474. doi: 10.1006/jmbi.1993.1294. [DOI] [PubMed] [Google Scholar]
  67. Zhang Z. Y., Poorman R. A., Maggiora L. L., Heinrikson R. L., Kézdy F. J. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J Biol Chem. 1991 Aug 25;266(24):15591–15594. [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES